In 2015, brexpiprazole was approved in the US for the treatment of schizophrenia in adults and for adjunctive treatment of major depressive disorder.
Is brexpiprazole FDA approved?
Brexpiprazole is FDA-approved for the treatment of schizophrenia with dose initiation starting at 1 mg once daily and titration to a target dose of 2 mg to 4 mg once daily. The titration schedule involves starting at 1 mg once daily for days 1 to 4, increasing to 2 mg once daily on days 5 to 7, and ending at 4 mg once daily on day 8 based upon the patient’s tolerability and clinical response.
How does brexpiprazole work?
Mar 23, 2018 · Brexpiprazole (Rexulti®, Otsuka Pharmaceutical Co, Ltd, Tokyo, Japan) is an atypical antipsychotic that was approved by the US Food and Drug Administration in July 2015 for treatment of schizophrenia and as an adjunctive therapy to antidepressant medications for the treatment of major depressive disorder (MDD).1 While the mechanism of action for …
What is brexpiprazole (Rexulti)?
Sep 30, 2019 · Brexpiprazole is being developed worldwide as an add-on therapy primarily for the treatment of depression and schizophrenia, but also for agitation and other behavioral symptoms in patients with Alzheimer's disease. In addition, it is being tested in people with bipolar and post-traumatic stress disorder. Findings
How effective is brexpiprazole for schizophrenia?
Brexpiprazole, a new antipsychotic drug approved by the U.S. Food and Drug Administration in July 2015 for the treatment of schizophrenia, is a novel serotonin-dopamine receptor modulator with partial agonist activity at serotonin 1A (5-HT 1A) and D 2/3 receptors. Areas covered: We reviewed brexpiprazole related in vitro and in vivo studies, including phase II and phase III …
What is brexpiprazole used to treat?
Brexpiprazole is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). It is also used with an antidepressant to treat depression when symptoms cannot be controlled by the antidepressant alone.
What is REXULTI approved for?
Lundbeck A/S (Lundbeck) announced that on July 10 (U.S. date) the U.S. Food and Drug Administration (FDA) approved REXULTI® (brexpiprazole) as an adjunctive therapy for the treatment of adults with major depressive disorder (MDD) and as a treatment for adults with schizophrenia.Jul 13, 2015
When was brexpiprazole FDA approved?
Approval Date: July 10, 2015.Aug 19, 2015
Is REXULTI approved for bipolar disorder?
No, Rexulti is not approved for bipolar disorder. The drug may be used off-label for this condition, but there are other medications that are approved for bipolar disorder and may be better options. (With off-label use, a drug is used to treat conditions other than those it's been approved to treat.)
What symptoms does REXULTI treat?
This medication is used to treat certain mental/mood disorders (such as schizophrenia, depression). Brexpiprazole helps you to think more clearly, feel less nervous, and take part in everyday life. It may also help to decrease hallucinations (hearing/seeing things that are not there).
How do you titrate brexpiprazole?
The recommended starting dosage for REXULTI as adjunctive treatment is 0.5 mg or 1 mg once daily, taken orally with or without food [see CLINICAL PHARMACOLOGY]. Titrate to 1 mg once daily, then up to the target dosage of 2 mg once daily.
Is brexpiprazole a narcotic?
Rexulti is not a controlled substance.Apr 13, 2020
What is the difference between Abilify and REXULTI?
Abilify (aripiprazole) is good for treating psychosis and mania, and can help with depression. It's less likely to cause side effects than other antipsychotics. Rexulti (brexpiprazole) does not cause as much weight gain as other similar medications. Fewer side effects compared to other similar medications.
How many atypical antipsychotics are there?
There are 6 atypical antipsychotics commercially available in the United States: clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole.
Which antipsychotic is best for bipolar disorder?
Olanzapine-fluoxetine combo (OFC) (Symbyax) Statistically speaking, OFC may be the most effective therapy for acute bipolar depression, with a number needed to treat (NNT) of 2 compared with 5 to 11 for other FDA-approved atypical antipsychotics.Jan 3, 2020
What is the best mood stabilizer for bipolar?
Lithium and quetiapine top the lists for all three phases of the illness: mania, depression, and the maintenance phase. Lurasidone and lamotrigine are either untested (lurasidone) or ineffective (lamotrigine) in mania, but they are essential tools for bipolar depression.May 13, 2020
What is a good mood stabilizer for bipolar?
Lamotrigine (Lamictal) may be the most effective mood stabilizer for depression in bipolar disorder, but is not as helpful for mania. The starting dose of lamotrigine should be very low and increased very slowly over four weeks or more.
When will the Brexpiprazole trial end?
To monitor safety, the U.S. study will offer a 12-week extension, the Japanese study a 14-week extension. The trials will finish in 2020 and 2021. For all trials of brexpiprazole, see clinicaltrials.gov.
Is brexpiprazole a partial agonist?
Brexpiprazole is an orally available dopamine receptor D2 partial agonist. This quinolinone derivative is a successor to aripiprazole (Abilify, Aripiprex), an approved, widely used drug that is also a dopamine D2 receptor partial agonist. Brexpiprazole is being developed worldwide as an add-on therapy primarily for the treatment of depression and schizophrenia, but also for agitation and other behavioral symptoms in patients with Alzheimer's disease. In addition, it is being tested in people with bipolar and post-traumatic stress disorder.
What is Rexulti FDA approved for?
Rexulti FDA Approval History. Rexulti (brexpiprazole) is a serotonin-dopamine activity modulator (SDAM) for the treatment of schizophrenia and the adjunctive treatment of major depressive disorder. Schizophrenia is a chronic mental illness that can cause delusions and hallucinations.
What is rexulti used for?
Rexulti (brexpiprazole) is a serotonin-dopamine activity modulator (SDAM) for the treatment of schizophrenia and the adjunctive treatment of major depressive disorder. Schizophrenia is a chronic mental illness that can cause delusions and hallucinations.
How many studies have been done on Rexulti?
The safety and efficacy of Rexulti was studied in four completed placebo-controlled clinical phase III studies – two studies as adjunctive therapy to antidepressants in MDD and two studies in schizophrenia.
How often should I take Rexulti?
Rexulti tablets are taken once daily with or without food. A lower dose is given to start, and then gradually increased over time to the target dosage. Common side effects include weight gain and akathisia, an inner sense of restlessness.
Is aripiprazole a second generation?
It is considered a second generation version of aripiprazole (Abilify), and with slightly different activity at the serotonin and dopamine receptors, could mean an improved clinical profile with fewer side effects such as restlessness.
Abstract
Introduction: Somatic symptom disorder (SSD) is a mental disorder that involves one or more physical symptoms (e.g.
1. Introduction
Disorders related to somatization have had a troubled history and have undergone multiple classifications and definitions from ancient to modern times.
2. Case description
Our patient is a 59-year-old female who presented to our centre with a psychiatric personal history of psychosis and current severe depressive symptoms, hyperarousal, anxiety, insomnia, comorbid obsessive-compulsive symptoms with polarization on gastrointestinal disorders, such as constipation, indigestion, abdominal bloating, and digestive difficulties, including circular thoughts related to a so-considered abnormal morphology of bowels, and long-lasting (2–3 h/day) rituals including use of laxatives, specific foods and beverages and cigarettes.
3. Discussion
To our knowledge, this is the first report to show the efficacy of brexpiprazole in improving depressive and anxiety symptoms in patients with an SSD.
4. Conclusion
These data indicate that adjunctive brexpiprazole 3 mg/day could be a safe and efficacious treatment option in reducing both depressive and anxiety symptoms in patients with clinically relevant symptomatology who have not responded to an SSRI therapy.
Patient consent for publication
Data in the manuscript were collected and reported with patient's informed consent.
CRediT authorship contribution statement
Stefania Chiappini: Conceptualization, Writing – original draft. Alessio Mosca: Conceptualization, Writing – original draft. Giovanni Martinotti: Conceptualization, Writing – review & editing. Francesco Di Carlo: Writing – review & editing. Andrea Miuli: Writing – original draft. Luigi Dattoli: Writing – review & editing.